Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer

被引：40
作者：
Luo, Hui-Yan [1 ,2 ,3 ]
Xu, Rui-Hua [1 ,2 ,3 ]
机构：
[1] Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
[2] State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China
[3] Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2014年 / 20卷 / 14期
关键词：
Biomarker; Target therapy; Predictive; Prognostic; Advanced colorectal cancer; GROWTH-FACTOR RECEPTOR; GENE COPY NUMBER; KRAS WILD-TYPE; EGFR MONOCLONAL-ANTIBODIES; CETUXIMAB PLUS IRINOTECAN; PHASE-III TRIAL; BEVACIZUMAB-INDUCED HYPERTENSION; ISLAND METHYLATOR PHENOTYPE; KIRSTEN RAS MUTATIONS; 1ST-LINE TREATMENT;
D O I：
10.3748/wjg.v20.i14.3858
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Colorectal cancer (CRC) is one of the most common human malignant diseases and the second leading cause of cancer-related deaths worldwide. The treatment of advanced CRC has improved significantly in recent years. With the emergence of two targeted antibodies, cetuximab (Erbitux), an anti-epidermal growth factor receptor monoclonal antibody and bevacizumab (Avastin), a vascular endothelial growth factor monoclonal antibody, the treatment of metastatic CRC has entered the era of personalized therapy. Predictive and prognostic biomarkers have, and will continue to, facilitate the selection of suitable patients and the personalization of treatment for metastatic CRC (mCRC). In this review, we will focus primarily on the important progresses made in the personalized treatment of mCRC and discuss the potentially novel predictive and prognostic biomarkers for improved selection of patients for anti-cancer treatment in the future. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
引用
收藏
页码：3858 / 3874
页数：17
相关论文
共 146 条
[1]   Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer [J].
Agrelo, Ruben ;
Cheng, Wen-Hsing ;
Setien, Fernando ;
Ropero, Santiago ;
Espada, Jesus ;
Fraga, Mario F. ;
Herranz, Michel ;
Paz, Maria F. ;
Sanchez-Cespedes, Montserrat ;
Artiga, Maria Jesus ;
Guerrero, David ;
Castells, Antoni ;
von Kobbe, Cayetano ;
Bohr, Vilheirn A. ;
Esteller, Manel .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (23) :8822-8827
[2]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[3]   Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].
Andreyev, HJN ;
Norman, AR ;
Cunningham, D ;
Oates, J ;
Dix, BR ;
Iacopetta, BJ ;
Young, J ;
Walsh, T ;
Ward, R ;
Hawkins, N ;
Beranek, M ;
Jandik, P ;
Benamouzig, R ;
Jullian, E ;
Laurent-Puig, P ;
Olschwang, S ;
Muller, O ;
Hoffmann, I ;
Rabes, HM ;
Zietz, C ;
Troungos, C ;
Valavanis, C ;
Yuen, ST ;
Ho, JWC ;
Croke, CT ;
O'Donoghue, DP ;
Giaretti, W ;
Rapallo, A ;
Russo, A ;
Bazan, V ;
Tanaka, M ;
Omura, K ;
Azuma, T ;
Ohkusa, T ;
Fujimori, T ;
Ono, Y ;
Pauly, M ;
Faber, C ;
Glaesener, R ;
de Goeij, AFPM ;
Arends, JW ;
Andersen, SN ;
Lövig, T ;
Breivik, J ;
Gaudernack, G ;
Clausen, OPF ;
De Angelis, P ;
Meling, GI ;
Rognum, TO ;
Smith, R .
BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696
[4]   Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study [J].
Andreyev, HJN ;
Norman, AR ;
Cunningham, D ;
Oates, JR ;
Clarke, PA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (09) :675-684
[5]  
[Anonymous], ZHONGGUO ZHONGLIU
[6]  
[Anonymous], J CLIN ONCOL
[7]  
[Anonymous], J CLIN ONCOL
[8]  
[Anonymous], 2010 GASTR CANC S JA
[9]  
[Anonymous], J CLIN ONCOL
[10]  
[Anonymous], J CLIN ONCOL
12345678910